HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mengjun Sui Selected Research

Neoplasms (Cancer)

9/2023Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
10/2021Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mengjun Sui Research Topics

Disease

2Neoplasms (Cancer)
09/2023 - 10/2021
1Thyroid Neoplasms (Thyroid Cancer)
09/2023
1Malaria
10/2021
1Hypoxia (Hypoxemia)
10/2021

Drug/Important Bio-Agent (IBA)

1NIMA-Interacting Peptidylprolyl IsomeraseIBA
09/2023
1VemurafenibIBA
09/2023
1Proto-Oncogene Proteins B-rafIBA
09/2023
1AlbuminsIBA
10/2021
1Atovaquone (Mepron)FDA Link
10/2021
1Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)IBA
10/2021

Therapy/Procedure

2Therapeutics
09/2023 - 10/2021
1Radiotherapy
10/2021
1Drug Therapy (Chemotherapy)
10/2021
1Immunotherapy
10/2021